Improving chemotherapy by reducing drug accumulation in healthy tissues
Reducing Off-Target Accumulation of Chemotherapeutic Nanomedicines
This study is looking at a new way to make chemotherapy work better and cause fewer side effects by using a natural immune response, which could help cancer patients get more effective treatment while protecting their healthy tissues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11050379 on NIH RePORTER |
What this research studies
This research investigates a new method to enhance chemotherapy effectiveness while minimizing side effects. It focuses on using a natural immune response to limit the accumulation of chemotherapy drugs in healthy tissues, allowing more of the drug to target tumors. The approach involves the use of a specific molecule, IFN-λ, which has shown promise in preclinical models to reduce toxicity and improve survival rates in tumor-bearing mice. By optimizing the delivery and timing of this treatment, the research aims to create a safer and more effective chemotherapy regimen for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing chemotherapy who are at risk of experiencing significant side effects from their treatment.
Not a fit: Patients who are not currently receiving chemotherapy or those with non-cancerous conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to chemotherapy treatments that are more effective against tumors while causing fewer adverse effects in healthy tissues.
How similar studies have performed: Other research has shown success in using immune responses to enhance drug delivery and reduce side effects, indicating that this approach has potential.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Anchordoquy, Thomas — University of Colorado Denver
- Study coordinator: Anchordoquy, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.